✦ LIBER ✦

P4-344: Oral curcumin for the treatment of mild-to-moderate Alzheimer's disease: Tolerability and clinical and biomarker efficacy results of a placebo-controlled 24-week study

✍ Scribed by Ringman, John M.; Cole, Greg; Teng, Edmond; Badmaev, Vladimir; Bardens, Jenny; Frautschy, Sally; Rosario, Emily; Fein, Jeff; Porter, Verna; Vanek, Zeba; Sugar, Catherine; Yau, Alice; Cummings, Jeffrey L.

Book ID: 123259734
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 53 KB
Volume: 4
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2008.05.2414

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A 24-week, randomized, double-blind, pla

A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease

✍ Nakamura, Yu; Imai, Yukimichi; Shigeta, Masahiro; Graf, Ana; Shirahase, Toru; Ki 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 54 KB

P.4.044 Long-term efficacy of donepezil

P.4.044 Long-term efficacy of donepezil in patients with mild to moderate Alzheimer's disease: Results from a one-year placebo-controlled study and two-year follow-up study

✍ B. Winblad; A. Wimo; A.-L. Wetterholm; A. Haglund; K. Engedal; H. Soininen; F.R. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 144 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre

P.4.006 Long-term efficacy and safety be

P.4.006 Long-term efficacy and safety benefits from treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease

✍ H.-J. Moebius; B. Reisberg; F. Schmitt; R. Doody 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 274 KB

Changes of biological markers and brain

Changes of biological markers and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24-week double-blind, randomized, placebo-controlled study

✍ Shifu Xiao; Tao Wang; Qiu Huang; Kewei Chen; Eric Reiman 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 52 KB

P.4.041 Donepezil is a well-tolerated lo

P.4.041 Donepezil is a well-tolerated long-term treatment for patients with mild to moderate Alzheimer's disease: Results from a patient cohort who completed a one-year placebo-controlled study and participated in a two-year follow-up study

✍ B. Winblad; K. Engedal; H. Soininen; F.R.J. Verhey; G. Waldemar; A. Wimo; A.-L. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 286 KB